{"id":3139,"date":"2021-02-16T13:05:08","date_gmt":"2021-02-16T13:05:08","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/technical-note\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\/"},"modified":"2025-11-26T14:18:43","modified_gmt":"2025-11-26T14:18:43","slug":"the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis","status":"publish","type":"technical-note","link":"https:\/\/www.sygnaturediscovery.com\/fr\/technical-note\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\/","title":{"rendered":"The ob\/ob H-FFC mouse model of NASH and fibrosis"},"content":{"rendered":"<p>Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. Patients with NAFLD have an increased risk of liver-related mortality, with approximately 9% of those with NASH developing cirrhosis, which can lead to end-stage liver disease. The risk factors for progressive NASH-related liver disease are obesity, type 2 diabetes, insulin resistance and older age. With no approved therapies for NASH this is an area of high unmet therapeutic need. When testing potential treatments of NASH it is important to consider not only the liver endpoints but also the associated co-morbidities.<\/p>\n<p>We have established and validated a model of NASH and fibrosis which combines the liver pathology alongside obesity and insulin resistance,\u00a0 the\u00a0<strong><em>ob\/ob<\/em><\/strong><strong>\u00a0H-FFC<\/strong>\u00a0mouse. In this model\u00a0<em>ob\/ob<\/em>\u00a0mice are maintained on a diet high in fat, fructose and cholesterol for 12 weeks. In this time they develop an increase in:<\/p>\n<p>\u00a0<\/p>\n<ul>\n<li>Plasma ALT and AST<\/li>\n<li>Liver lipids and collagen content<\/li>\n<li>Histological end points: lipid deposition, lobular inflammation, overall NAS score and moderate to marked fibrosis<\/li>\n<\/ul>\n<p>The\u00a0<em>ob\/ob<\/em>\u00a0H-FFC mouse has been validated with the peroxisome proliferator activated receptor (PPAR) gamma agonist, pioglitazone, and the dual PPAR alpha\/delta agonist, elafibranor.<\/p>\n<h3><strong>The <em>ob\/ob<\/em> H-FFC mouse model of NASH and fibrosis has all the liver hallmarks of the disease observed in man<\/strong><\/h3>\n<p><img decoding=\"async\" class=\"aligncenter size-full wp-image-10305\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/The-obob-H-FFC-mouse-model-of-NASH-and-fibrosis-has-all-the-liver-hallmarks-of-the-disease-observed-in-man.png\" alt=\"\"><\/p>\n<p>Mean and SEM (n=11-13). Significances vs\u00a0<em>ob\/ob<\/em>\u00a0standard chow vehicle are denoted by *p&lt;0.05, **p&lt;0.01 and ***p&lt;0.001. Significances vs\u00a0<em>ob\/ob<\/em>\u00a0H-FFC vehicle are denoted by \u2020\u2020p&lt;0.01 and \u2020\u2020\u2020p&lt;0.001.<br>\n* The NAFLD activity score (NAS) generated by combining scores for # parameters;\u00a0steatosis, hepatocellular ballooning and lobular inflammation.<\/p>\n<h3><strong>The <em>ob\/ob<\/em> H-FFC mouse develops bridging fibrosis which can be inhibited by pioglitazone and elafibranor<\/strong><\/h3>\n<p><img decoding=\"async\" class=\"aligncenter size-full wp-image-10306\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/The-obob-H-FFC-mouse-develops-bridging-fibrosis-which-can-be-inhibited-by-pioglitazone-and-elafibranor.png\" alt=\"\"><\/p>\n<p>Representative images from the NASH and fibrosis rodent model. Sirius red stained liver sections, magnification 20x demonstrating the difference between the\u00a0<em>ob\/ob<\/em>\u00a0vehicle,\u00a0<em>ob\/ob<\/em>\u00a0H-FFC vehicle, <em>ob\/ob<\/em> H-FFC pioglitazone po bid and <em>ob\/ob<\/em> H-FFC elafibranor po qd groups<\/p>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Explore NASH &#038; fibrosis in ob\/ob H-FFC mouse model. Validate treatments for liver disease, obesity, insulin resistance, and co-morbidities.<\/p>\n","protected":false},"featured_media":3140,"template":"","category":[1],"resource_tag":[],"class_list":["post-3139","technical-note","type-technical-note","status-publish","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The ob\/ob H-FFC mouse model of NASH and fibrosis - Sygnature<\/title>\n<meta name=\"description\" content=\"Explore NASH &amp; fibrosis in ob\/ob H-FFC mouse model. Validate treatments for liver disease, obesity, insulin resistance, and co-morbidities.\" \/>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The ob\/ob H-FFC mouse model of NASH and fibrosis - Sygnature\" \/>\n<meta property=\"og:description\" content=\"Explore NASH &amp; fibrosis in ob\/ob H-FFC mouse model. Validate treatments for liver disease, obesity, insulin resistance, and co-morbidities.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/technical-note\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T14:18:43+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/The-obob-H-FFC-mouse-model-of-NASH-and-fibrosis-has-all-the-liver-hallmarks-of-the-disease-observed-in-man.png\" \/>\n\t<meta property=\"og:image:width\" content=\"939\" \/>\n\t<meta property=\"og:image:height\" content=\"550\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/technical-note\\\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/technical-note\\\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\\\/\",\"name\":\"The ob\\\/ob H-FFC mouse model of NASH and fibrosis - Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/technical-note\\\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/technical-note\\\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/The-obob-H-FFC-mouse-model-of-NASH-and-fibrosis-has-all-the-liver-hallmarks-of-the-disease-observed-in-man.png\",\"datePublished\":\"2021-02-16T13:05:08+00:00\",\"dateModified\":\"2025-11-26T14:18:43+00:00\",\"description\":\"Explore NASH & fibrosis in ob\\\/ob H-FFC mouse model. Validate treatments for liver disease, obesity, insulin resistance, and co-morbidities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/technical-note\\\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/technical-note\\\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/technical-note\\\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/The-obob-H-FFC-mouse-model-of-NASH-and-fibrosis-has-all-the-liver-hallmarks-of-the-disease-observed-in-man.png\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/The-obob-H-FFC-mouse-model-of-NASH-and-fibrosis-has-all-the-liver-hallmarks-of-the-disease-observed-in-man.png\",\"width\":939,\"height\":550},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/technical-note\\\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The ob\\\/ob H-FFC mouse model of NASH and fibrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The ob\/ob H-FFC mouse model of NASH and fibrosis - Sygnature","description":"Explore NASH & fibrosis in ob\/ob H-FFC mouse model. Validate treatments for liver disease, obesity, insulin resistance, and co-morbidities.","robots":{"index":"noindex","follow":"follow"},"og_locale":"fr_CA","og_type":"article","og_title":"The ob\/ob H-FFC mouse model of NASH and fibrosis - Sygnature","og_description":"Explore NASH & fibrosis in ob\/ob H-FFC mouse model. Validate treatments for liver disease, obesity, insulin resistance, and co-morbidities.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/technical-note\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\/","og_site_name":"Sygnature","article_modified_time":"2025-11-26T14:18:43+00:00","og_image":[{"width":939,"height":550,"url":"http:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/The-obob-H-FFC-mouse-model-of-NASH-and-fibrosis-has-all-the-liver-hallmarks-of-the-disease-observed-in-man.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/technical-note\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/technical-note\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\/","name":"The ob\/ob H-FFC mouse model of NASH and fibrosis - Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/technical-note\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/technical-note\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/The-obob-H-FFC-mouse-model-of-NASH-and-fibrosis-has-all-the-liver-hallmarks-of-the-disease-observed-in-man.png","datePublished":"2021-02-16T13:05:08+00:00","dateModified":"2025-11-26T14:18:43+00:00","description":"Explore NASH & fibrosis in ob\/ob H-FFC mouse model. Validate treatments for liver disease, obesity, insulin resistance, and co-morbidities.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/technical-note\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/technical-note\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/technical-note\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/The-obob-H-FFC-mouse-model-of-NASH-and-fibrosis-has-all-the-liver-hallmarks-of-the-disease-observed-in-man.png","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/The-obob-H-FFC-mouse-model-of-NASH-and-fibrosis-has-all-the-liver-hallmarks-of-the-disease-observed-in-man.png","width":939,"height":550},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/technical-note\/the-ob-ob-h-ffc-mouse-model-of-nash-and-fibrosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"The ob\/ob H-FFC mouse model of NASH and fibrosis"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/technical-note\/3139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/technical-note"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/technical-note"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/technical-note\/3139\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/3140"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=3139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=3139"},{"taxonomy":"resource_tag","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/resource_tag?post=3139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}